|
|
|
LifeScienceHistory.com - Check us out on Instagram
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Fate Therapeutics, Inc.
| | | Phone: | (858) 875-1800 | Fax: | (858) 875-1833 | Year Established: | 2007 | Employees: | 25 | Ticker: | FATE | Exchange: | NASDAQ | Main Contact: | Scott Wolchko, President, CEO & CFO | | Other Contacts: | Jim Beitel, Senior VP, Corporate Development Chris M. Storgard, M.D., CMO Stewart Abbot, Ph.D., Chief Development Officer Bob Valamehr, Ph.D., VP, Cancer Immunotherapy Cindy Tahl, J.D., General Counsel Dan Shoemaker, Ph.D., CSO
| | Company Description | Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop stem cell modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. The Company’s award-winning, proprietary iPSC technology platform incorporates the most advanced viral, small molecule and protein reprogramming methods and offers a highly efficient, minimally invasive system to recapitulate human physiology for commercial-scale drug discovery and therapeutic use. The Company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. Fate Therapeutics is currently conducting a Phase 1b clinical trial of FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies, such as leukemia and lymphoma. | |
|
|
|
|
|